Diverchim Acquires Innoverda to Advance Sustainable Drug Substance Development
Diverchim, a renowned French Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of Innoverda, a Contract Research Organization (CRO) known for its electrochemical
Biotech Manufacturing Strategy: Key Questions Investors Ask & Why They Matter
Manufacturing strategy has become a critical differentiator in biotech funding rounds, directly impacting company valuation and exit opportunities. This guide helps biotech leaders prepare for
CDMO European Landscape 2025 [Infographic]
An analysis of the CDMOs operating facilities in Europe, by Small Molecule, Biologics and Cell & Gene Therapty
Be Bio Secures $92M Series C Funding to Advance BCM Therapies
Be Bio, has successfully closed a $92 million Series C financing round. The funding was backed by new investor Nextech, along with existing investors such
Granata Bio Secures $15M Series A+ to Advance Reproductive Health Innovation
Granata Bio Corporation, a biopharma company addressing the global infertility medication market valued at $3.6 billion, has successfully closed a $15 million Series A+ funding
Tanvex BioPharma Completes Acquisition of Bora Biologics
Tanvex BioPharma, Inc. has announced the completion of its acquisition of Bora Biologics Co., Ltd., a subsidiary of Bora Pharmaceuticals. The combined entity’s CDMO services
Tune Therapeutics Secures $175M Financing to Accelerate Epigenome Editing Pipeline
Tune Therapeutics, a leading epigenome editing company, has secured over $175 million in financing to further the development of its innovative therapies targeting chronic and
Immunis, Inc. Raises $25 Million to Advance IMM01-STEM in Elderly Patients
Immunis, Inc., a clinical-stage biotechnology company focused on developing multi-active biologics for immune-related diseases, has raised $25 million in its Series A-1 financing round. This
Ouro Medicines Launches with $120M Funding to Advance Immune Reset Therapies
Ouro Medicines has officially launched with $120 million in funding to develop immune reset therapeutics for chronic immune-mediated diseases. The Series A funding round was
Windward Bio Launches with $200M Backing to Advance WIN378 for Severe Asthma
Windward Bio has officially launched, announcing the close of a $200 million Series A financing round. The funding is led by OrbiMed, Novo Holdings, and
Stay ahead of trends and best practices
